The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases

Retnakumar, Sruthi Vijaya; Chauvin, Céline; Bayry, Jagadeesh

doi:10.1016/j.pharmthera.2023.108399

Cited by 12 publications

(3 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the most promising treatment modality, tumor immunotherapy has been proven to be clinically effective in cancer fighting. In the midst of various immunotherapies, immune checkpoint blocking therapy, such as anti-Programmed Death 1 (αPD-1), anti-Programmed Death Ligand 1 (αPD-L1), anti-Cytotoxic T-Lymphocyte Antigen 4 (αCTLA-4), anti-Lymphocyte activation gene-3 (αLAG-3), anti-T cell immunoglobulin-3 (αTIM-3) and anti-T cell immunoreceptor with Ig and ITIM domains (αTIGIT), present successful therapeutic results in the treatment of many advanced malignancies by blocking the inhibitory pathways of immune cells [ 32 – 34 ]. Since the CTLA-4-targeting ipilimumab came on the market in 2013, the FDA has approved seven immune checkpoint inhibitors for the treatment of more than 20 cancer species [ 35 ].…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy

Dong,

Xue,

Yan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Radiotherapy (RT) plays an important role in tumor therapy due to its noninvasiveness and wide adaptation. In recent years, radiation therapy has been discovered to induce an anti-tumor immune response, which arouses widespread concern among scientists and clinicians. In this review, we highlight recent advances in the applications of nano-biomaterials for radiotherapy-activated immunotherapy. We first discuss the combination of different radiosensitizing nano-biomaterials and immune checkpoint inhibitors to enhance tumor immune response and improve radiotherapy efficacy. Subsequently, various nano-biomaterials-enabled tumor oxygenation strategies are introduced to alleviate the hypoxic tumor environment and amplify the immunomodulatory effect. With the aid of nano-vaccines and adjuvants, radiotherapy refreshes the host's immune system. Additionally, ionizing radiation responsive nano-biomaterials raise innate immunity-mediated anti-tumor immunity. At last, we summarize the rapid development of immune modulatable nano-biomaterials and discuss the key challenge in the development of nano-biomaterials for tumor radio-immunotherapy. Understanding the nano-biomaterials-assisted radio-immunotherapy will maximize the benefits of clinical radiotherapy and immunotherapy and facilitate the development of new combinational therapy modality. Graphical Abstract

show abstract

Section: Introductionmentioning

confidence: 99%

Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy

Dong,

Xue,

Yan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…In fact, irAEs are known to occur in cancer patients who receive ICIs. Due to the overstimulation of the immune system during vaccination, it remains imperative to consider the possibility of irAEs and exercise caution when treating such patients [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors

Yang

2023

Cell Death Dis

View full text Add to dashboard Cite

Cancer patients are susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Different antitumor treatments have attracted wide attention in the context of coronavirus disease 2019 (COVID-19), especially immune checkpoint inhibitors (ICIs) that have revolutionized oncology changes. It may also have protective and therapeutic roles in viral infections. In this article, we collected 26 cases of SARS-CoV-2 infection during ICIs therapy and 13 related to COVID-19 vaccination from Pubmed, EMBASE, and Wed of Science. Of these 26 cases, 19 (73.1%) presented mild cases and 7 (26.9%) were severe cases. Melanoma (47.4%) was a common cancer type in mild cases and lung cancer (71.4%) in severe cases (P = 0.016). The results showed that their clinical outcomes varied widely. Although there are similarities between the immune checkpoint pathway and COVID-19 immunogenicity, ICIs therapy overactivated T cells, which often leads to immune-related adverse events. In fact, the COVID-19 vaccine has been shown to be safe and effective in patients treated with ICIs. In this review, we report the vital clinical observations of SARS-CoV-2 infection or vaccination in cancer patients treated with ICIs and explore the potential interaction between them.

show abstract

“…Notably, when PD-L1 combines with PD-1 on tumor cells, it suppresses the proliferation and death of activated T cells, which leads to an ICP response. [10][11][12] Moreover, ICP responses have been reported to promote T-cell apoptosis, negatively regulate the secretion of the cytokine interleukin-2 (IL-2), and enhance tumor immune escape, thereby facilitating tumor growth. 13,14 Importantly, the PD-1/PD-L1 pathway plays a pivotal role in modulating HCC immune escape.…”

Section: Introductionmentioning

confidence: 99%

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Hou,

Xu,

et al. 2023

BioFactors

View full text Add to dashboard Cite

Immune checkpoints (ICPs) can promote tumor growth and prevent immunity‐induced cancer cell apoptosis. Fortunately, targeting ICPs, such as programmed cell death 1 (PD‐1) or cytotoxic T lymphocyte associated protein 4 (CTLA‐4), has achieved great success in the past few years and has gradually become an effective treatment for cancers, including hepatocellular carcinoma (HCC). However, many patients do not respond to ICP therapy due to acquired resistance and recurrence. Therefore, clarifying the specific mechanisms of ICP in the development of HCC is very important for enhancing the efficacy of anti‐PD‐1 and anti‐CTLA‐4 therapy. In particular, antigen presentation and interferon‐γ (IFN‐γ) signaling were reported to be involved in the development of resistance. In this review, we have explained the role and regulatory mechanisms of ICP therapy in HCC pathology. Moreover, we have also elaborated on combinations of ICP inhibitors and other treatments to enhance the antitumor effect. Collectively, recent advances in the pharmacological targeting of ICPs provide insights for the development of a novel alternative treatment for HCC.

show abstract

The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases

Cited by 12 publications

References 122 publications

Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy

Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy

SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Contact Info

Product

Resources

About